The use of the foreign decisions pathway will be more efficient. The products coming in through that pathway would take 90 days to review. Products that require a full assessment would take a bit longer to review—180 to 210 days, as an example.
However, we do have other abbreviated pathways that Canadian companies can use. Two of the pathways that would rely on a smaller set of evidence that Canadian companies can use would be a 45-day review or a 60-day review, based on standards that Health Canada sets in advance. As long as the Canadian company can follow those standards, then they can also use those pathways, which would be faster than the use of a foreign review decision pathway.